DHA-PQP dispersible

Alfasigma

Legend
Product category

  • Artemisinin-based Combination Therapy (ACT)

  • Dihydroartemisinin-piperaquine
Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in children and infants >5kg
Dosing

  • Once-daily for 3 days
Efficacy

  • Still under investigation

  • 28-day PCR-corrected ACPR* 94.7–99.9% (TBC)

  • 42-day PCR-corrected ACPR* 91.5–99.3% (TBC)
Key features

  • Anticipated comparatively long post-treatment protection
Challenges

  • Cardiac monitoring restrictions 

  • Confirmed piperaquine resistance in Greater Mekong Sub-region (GMS)
Status

  • Pharmacokinetic studies in children completed 

  • Dossier under development for submission to EMA
Next milestone

  • Submission to EMA planned for end 2018 / beginning 2019 

* ACPR = adequate clinical and parasitological response